2-Chloro-4-fluoronitrobenzene | CAS:2106-50-5

We serve 2-Chloro-4-fluoronitrobenzene CAS:2106-50-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Chloro-4-fluoronitrobenzene

Chemical Name:2-Chloro-4-fluoronitrobenzene
CAS.NO:2106-50-5
Synonyms:2-Chloro-4-fluoronitrobenzene
2-chloro-4-fluoro-1-nitrobenzene
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 236.4±20.0 °C at 760 mmHg
Melting Point 34-37ºC
Molecular Formula C6H3ClFNO2
Molecular Weight 175.545
Flash Point 96.8±21.8 °C
Vapour Pressure 0.1±0.5 mmHg at 25°C
Index of Refraction 1.555
 
Specification:
Appearance:Light yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2-Chloro-4-fluoronitrobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-chloro-4-fluoro-1-nitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Chloro-4-fluoronitrobenzene Use and application,2-chloro-4-fluoro-1-nitrobenzene technical grade,usp/ep/jp grade.


Related News: Here’s what we can tell you so far:Isobutyl Chloroformate manufacturer But several border points remain open, and many medical workers fear that Hong Kong’s well-regarded health care system will be overwhelmed.Diethoxyphosphorylmethyl 4-methylbenzenesulfonate supplier We manufacture APIs and drug manufacturers make medicines from APIs.Guanosine 5'-monophosphate disodium salt vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.From a global perspective, China’s API companies have also performed well. According to the report of the American Transparent Medicine website, in 2016 the top ten pharmaceutical companies in the global API market, Chinese pharmaceutical companies accounted for 6 seats.